Grace Therapeutics (NASDAQ: GRCE) owner buys shares in three-day Form 4

What happened

Grace Therapeutics, Inc. (NASDAQ: GRCE) filed a Form 4 showing Opaleye Management Inc. bought 71,065 shares from 10/14/2026 to 10/16/2026. The reported weighted average prices were $1.9349 on 10/14/2026, $1.9453 on 10/15/2026 and $1.8917 on 10/16/2026, for about $136,178.

After the trades, Opaleye Management Inc. held 2,944,354 shares, all indirectly through Opaleye, L.P. The filing identifies Opaleye Management Inc. as a 10% owner of Grace Therapeutics, Inc.

Key numbers

Metric	Latest	Change	Source
Shares bought	71,065 shares		SEC Form 4
Total purchase value	about $136,178		SEC Form 4
Post-trade holdings	2,944,354 shares		SEC Form 4
Purchase price range	$1.89 to $1.95 per share		SEC Form 4

Read more: Grace Therapeutics (GRCE) stock analysis and investment case

Why it matters

OptimistFi's case is that Grace works if its novel drug-delivery approach creates approvable rare-disease products before cash burn or dilution overwhelms holders. This filing is mixed because it adds a new purchase from a 10% owner, but it is still only an ownership report.

OptimistFi calculates the 71,065 shares were about 2.5% of the holding before the trade, so the buy is small rather than decisive. The purchases came in three pieces, with 11,233 shares on 10/14/2026, 23,485 shares on 10/15/2026 and 36,347 shares on 10/16/2026.

The prices stayed close together. The reported ranges were $1.90 to $1.98, $1.90 to $1.95 and $1.89 to $1.90. The weighted average price on 10/16/2026 was the lowest of the three sessions, at $1.8917.

The filing also gives the intraday ranges, from $1.90 to $1.98 on 10/14/2026, from $1.90 to $1.95 on 10/15/2026 and from $1.89 to $1.90 on 10/16/2026. The transaction code is P, which the filing uses for purchases, and James Silverman signed the form on 10/16/2026.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

The next quarterly report is the next dated test from the evidence. A report that shows progress on the drug-delivery approach or less pressure from cash burn would strengthen the case.

If the next report does not add that kind of update, this filing remains an ownership signal rather than a business update. For now, the purchase leaves the investment case unchanged except for the new ownership data point.

More from OptimistFi

• GRCE stock: the Grace Therapeutics thesis, its status and the next test to watch
• Stock research on every company OptimistFi covers

From OptimistFi Perps